Reaction
Hepatic Cancer Metastatic reporting signals
As of the last recalculation, Hepatic Cancer Metastatic appears in 852 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 39.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sorafenib | 32 | 39.1 | 39.1 |
| Ado-Trastuzumab Emtansine | 6 | 17.5 | 17.5 |
| Panitumumab | 11 | 17.4 | 17.4 |
| Everolimus Tablets | 10 | 14.7 | 14.7 |
| Regorafenib | 6 | 12.7 | 12.7 |
| Lapatinib | 8 | 12.7 | 12.7 |
| Sofosbuvir | 9 | 11.3 | 11.3 |
| Capecitabine | 39 | 10.9 | 10.9 |
| Entecavir | 5 | 10.5 | 10.5 |
| Erlotinib Hydrochloride | 5 | 9.8 | 9.8 |
| Temozolomide | 8 | 9.4 | 9.4 |
| Trifluridine And Tipiracil | 3 | 6.9 | 6.9 |
| Ledipasvir And Sofosbuvir | 4 | 5.1 | 5.1 |